Collectively, these findings indicate that targeting ARRB1-△exon13 may constitute a significant anti-tumor strategy, particularly for GBMs that depend on glycolysis for energy, thereby allowing for the simultaneous targeting of cancer metabolism. Here, ARRB1 is linked to neoplasm.